Junling Li

34PUBLICATIONS
55CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsNeurology and neuromuscular diseasesEpigenetics (incl. genome methylation and epigenomics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (34)

|Mar 20, 2026
TP53 CpG Site Mutations Predict the Survival of First-Line Chemoimmunotherapy in Advanced Lung Adenocarcinoma.

Lige Wu, Zihua Zou, Yan Li

|Feb 09, 2026
Efficacy and safety of lorlatinib in first-line and subsequent-line treatments for patients with ALK-positive non-small cell lung cancer: a single-center real-world study in China.

Lige Wu, Jiayu Liu, Zihua Zou

|Aug 11, 2025
Efficacy and Safety of Afatinib Plus Bevacizumab as First-Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial.

Huiyang Shi, Miaohan Wang, Junling Li

|Jun 03, 2025
DNAJA: emerging targets for anti-tumor therapy.

Lige Wu, Puyuan Xing, Junling Li

|May 12, 2025
A Real-World Study: Therapeutic Outcomes of ROS1-Positive Advanced NSCLC.

Hanqi Yuan, Zihua Zou, Xuezhi Hao

|May 11, 2025
Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: a multicenter cohort study.

Puyuan Xing, Xingxiang Pu, Yu Zhou

Pageof 6

Frequent Collaborators

14 joint publications

Puyuan Xing

6 joint publications

Yan Wang

6 joint publications

Ziyi Xu

5 joint publications

Zihua Zou